• Home
  •  / Caribou Biosciences

Caribou Biosciences

OverviewSuggest Edit

Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

TypePrivate
Founded2011
HQBerkeley, CA, USMap
Websitecariboubio.com
Employee Ratings3.1More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Jan 2021)63
Cybersecurity ratingCMore

Key People/Management at Caribou Biosciences

Rachel Haurwitz

Rachel Haurwitz

President and Chief Executive Officer
Barbara McClung

Barbara McClung

Chief Legal Officer and Corporate Secretary
Steven Kanner

Steven Kanner

Chief Scientific Officer
Chris Fuller

Chris Fuller

Vice President of Informatics
Cherry Thomas

Cherry Thomas

Senior Vice President of Clinical Development
Scott Gradia

Scott Gradia

Vice President of Platform Research
Show more

Caribou Biosciences Office Locations

Caribou Biosciences has an office in Berkeley
Berkeley, CA, US (HQ)
2929 Seventh Street
Show all (1)

Caribou Biosciences Financials and Metrics

Summary Metrics

Founding Date

2011

Caribou Biosciences total Funding

$44.5 m

Caribou Biosciences latest funding size

$30 m

Time since last funding

5 years ago

Caribou Biosciences investors

Maverick Capital, Heritage Group, Novartis, Jenny Rooke, Mission Bay Capital, Anterra Capital, 5 Prime Ventures, F-Prime Capital Partners, Pontifax AgTech
Caribou Biosciences's latest funding round in May 2016 was reported to be $30 m. In total, Caribou Biosciences has raised $44.5 m
Show all financial metrics

Caribou Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

Learn more about our premium products
SecurityScorecard logo

Caribou Biosciences Online and Social Media Presence

Caribou Biosciences's Trends

Embed Graph

Caribou Biosciences News and Updates

September 19, 2019

Oxford Nanopore Announces That It Has Entered Into a Non-exclusive Agreement With Caribou Biosciences for CRISPR-Cas9 Enrichment for Nanopore Sequencing

OXFORD, England, Sept. 19, 2019 /PRNewswire/ -- Oxford Nanopore and Caribou Biosciences, Inc. have entered into a non-exclusive license agreement under which Caribou has granted Oxford Nanopore a worldwide, non-exclusive license under foundational CRISPR-Cas9 intellectual property...
April 29, 2019

Caribou Biosciences CEO, Rachel Haurwitz will talk CRISPR’s present and future applications at DisruptSF

Seven years ago, Rachel Haurwitz finished her last day as a student in the University of California laboratory where she helped conduct some of the pioneering research on the gene editing technology known as CRISPR, and became employee number one at Caribou Biosciences, a company founded to commerci…
October 24, 2018

Global CRISPR in Agriculture Market - Caribou Biosciences, Inc.,Cibus,Monsanto,Bayer AG

The Report “CRISPR in Agriculture Market 2025” provides Key Benefits, Key Market Segments, Secondary and Primary Research, Analyst Tools and Models to 2025. The Report will assist Reader with Better Understanding and Decision Making. Posted via Industry Today. Follow us on Twitter @IndustryToday
September 10, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affi…

 Caribou Biosciences Frequently Asked Questions

  • When was Caribou Biosciences founded?

    Caribou Biosciences was founded in 2011.

  • Who are Caribou Biosciences key executives?

    Caribou Biosciences's key executives are Rachel Haurwitz, Barbara McClung and Steven Kanner.

  • How many employees does Caribou Biosciences have?

    Caribou Biosciences has 63 employees.

  • Who are Caribou Biosciences competitors?

    Competitors of Caribou Biosciences include Biocytogen, Definigen and Covalab.

  • Where is Caribou Biosciences headquarters?

    Caribou Biosciences headquarters is located at 2929 Seventh Street, Berkeley.

  • Where are Caribou Biosciences offices?

    Caribou Biosciences has an office in Berkeley.

  • How many offices does Caribou Biosciences have?

    Caribou Biosciences has 1 office.